阿尔茨海默病的基础知识:我们都应该知道
1School of Computer and Systems Sciences, Jawaharlal Nehru University, New Delhi, India.
Neurological research
|July 10, 2025
概括
阿尔茨海默病涉及蛋白质的积累和神经炎症. 单克隆抗体在减缓认知衰退方面表现有希望,但需要对患者进行仔细的选择和安全监测才能有效治疗.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,影响全球数百万人的渐进性认知能力下降.
- 病理学特征包括粉样β (Aβ) 斑块,蛋白的神经纤维状 (NFT) 和慢性神经炎症.
研究的目的:
- 审查导致阿尔茨海默病的分子,遗传和免疫因素.
- 专注于致病性蛋白质,质细胞的作用和当前的单克隆抗体 (mAb) 疗法.
主要方法:
- 关键参与者的文献综述:Aβ,tau,微质细胞和星球细胞.
- 对基因突变 (APP,PSEN1,PSEN2,APOE,BACE1,MAPT) 的分析及其影响.
- 对抗Aβ mAbs (aducanumab,lecanemab,donanemab) 的临床试验数据的审查.
主要成果:
- 神经炎症加剧AD病理,导致突触损失和神经元死亡.
- 单克隆抗体显示出降低Aβ负担和减缓认知衰退的潜力 (例如,donanemab,lecanemab).
- 像ARIA这样的不良事件是显著的,特别是在APOE-4载体中;阿杜卡努马布的治疗已停止.
结论:
- 阿尔茨海默病是多因素的,涉及蛋白质聚合,免疫反应和遗传倾向.
- mAb疗法具有疾病修饰的潜力,但需要精确的患者分层和安全监测.
- 未来的战略需要个性化,组合的方法,整合生物标志物和高级技术来管理AD.
相关概念视频
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Dementia
173
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
173
Parkinson's Disease: Overview
716
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
Role of Neurotransmitters in Memory
1.0K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
1.0K
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K


